score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Preclinical			Copy Number	CDKN2A	Deletion				0.0	0.0		Putatively Actionable	EPZ015666	PRMT5 inhibition	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214													0				CDKN2A Deletion		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.G761D	0.0105	762.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0				BRAF p.G761D (Missense)	1.0	MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.A59T	0.3679	299.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0.0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				NRAS p.A59T (Missense)	1.0	MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat151		
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G574E	0.0606	66.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846						0				ALK p.G574E (Missense)		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.V715M	0.0784	51.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0.0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1	0				JAK1 p.V715M (Missense)		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.G655D	0.0784	51.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0.0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1	0				JAK1 p.G655D (Missense)		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.R811H	0.0514	253.0	5.7999999999999994e-05	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881													0				MET p.R811H (Missense)	0.0	MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.G890D	0.2591	220.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881													0				MET p.G890D (Missense)	0.0	MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.V2284I	0.06	100.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007													0				ATM p.V2284I (Missense)	1.0	MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.A713T	0.3741	139.0	0.0	0.0																Investigate Actionability	1.0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				SF3B1 p.A713T (Missense)		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.A341V	0.0538	93.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1.0	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf	0				IDH1 p.A341V (Missense)		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK1	Missense	p.R181K	0.0621	177.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0				CHEK1 p.R181K (Missense)	1.0	MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51C	Missense	p.A55V	0.0402	323.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0				RAD51C p.A55V (Missense)	1.0	MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Investigate Actionability	FDA-Approved			Somatic Variant	RAD54L	Missense	p.T317I	0.2596	104.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf													0				RAD54L p.T317I (Missense)	0.0	MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.A1129T	0.253	83.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf													0				TSC1 p.A1129T (Missense)		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Missense	p.G402D	0.0248	282.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0				BRCA2 p.G402D (Missense)		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Missense	p.A3176V	0.0202	396.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0				BRCA2 p.A3176V (Missense)		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.V143I	0.0405	148.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MSH6 p.V143I (Missense)		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.E544K	0.3873	142.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MSH6 p.E544K (Missense)		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Nonsense	p.Q835*	0.3368	95.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MSH6 p.Q835* (Nonsense)		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.V804A	0.2103	214.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951													0				PBRM1 p.V804A (Missense)		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.A177V	0.0216	231.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MLH3 p.A177V (Missense)		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.S170N	0.0301	332.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	Peng W, Chen JQ, Liu C, et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016;6(2):202-16.	https://doi.org/10.1158/2159-8290.CD-15-0283	Investigate Actionability	0.0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310	0				PTEN p.S170N (Missense)	1.0	MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Splice Site		0.040999999999999995	122.0	0.0	0.0																Investigate Actionability	0.0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				PRPF8  (Splice Site)		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Investigate Actionability			Clinical evidence	Copy Number	ESR1	Deletion				0.0	0.0																Investigate Actionability	0.0	Ampifications of ESR1 was significantly associated with poor disease-free survival and overall survival in a study of 99 patients with ER-positive breast cancer tumors.	Nielsen KV, Ejlertsen B, Muller S, et al. Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. Breast Cancer Res Treat. 2011;127(2):345-55.	https://doi.org/10.1007/s10549-010-0984-y	0				ESR1 Deletion		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	
Biologically Relevant				Somatic Variant	TACC3	Missense	p.D709N	0.0345	116.0	0.0	0.0																					0				TACC3 p.D709N (Missense)		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Biologically Relevant				Somatic Variant	PMS2	Missense	p.D286N	0.018000000000000002	334.0	0.0	0.0																					0				PMS2 p.D286N (Missense)		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Biologically Relevant				Somatic Variant	PMS2	Missense	p.G232E	0.0211	331.0	0.0	0.0																					0				PMS2 p.G232E (Missense)		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Biologically Relevant				Somatic Variant	CD274	Missense	p.T221I	0.1419	155.0	0.0	0.0																					0				CD274 p.T221I (Missense)		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Biologically Relevant				Somatic Variant	PAK1	Missense	p.G510D	0.0657	213.0	0.0	0.0																					0				PAK1 p.G510D (Missense)		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Biologically Relevant				Somatic Variant	RB1	Missense	p.V833I	0.0312	224.0	0.0	0.0																					0				RB1 p.V833I (Missense)		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.A282V	0.0476	105.0	0.0	0.0																					0				NTRK3 p.A282V (Missense)		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Biologically Relevant				Somatic Variant	NF1	Missense	p.P2303S	0.0203	246.0	0.0	0.0																					0				NF1 p.P2303S (Missense)		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Biologically Relevant				Somatic Variant	NF1	Missense	p.G2499D	0.0296	169.0	0.0	0.0																					0				NF1 p.G2499D (Missense)		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G836D	0.0619	113.0	0.0	0.0																					0				COL1A1 p.G836D (Missense)		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Biologically Relevant				Somatic Variant	BRD4	Missense	p.S401N	0.1243	169.0	0.0	0.0																					0				BRD4 p.S401N (Missense)		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Biologically Relevant				Somatic Variant	AURKA	Missense	p.P106S	0.0276	217.0	0.0	0.0																					0				AURKA p.P106S (Missense)		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Biologically Relevant				Somatic Variant	PDGFB	Missense	p.S75N	0.1538	169.0	0.0	0.0																					0				PDGFB p.S75N (Missense)		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	MEL-IPI_Pat151-Normal-SM-5VWIB
Biologically Relevant				Copy Number	PDGFB	Amplification				0.0	0.0																					0				PDGFB Amplification		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	
Biologically Relevant				Copy Number	ROS1	Deletion				0.0	0.0																					0				ROS1 Deletion		MEL-IPI_Pat151	MEL-IPI_Pat151-Tumor-SM-7A15A	
Biologically Relevant				Microsatellite Stability	Supporting variants		MSH6 p.Q835* (Nonsense), PRDM2 p.278_278E>EE (Insertion), PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: MSH6 p.Q835* (Nonsense), PRDM2 p.278_278E>EE (Insertion), PRDM2 p.703_704insP (Insertion)		MEL-IPI_Pat151		
Biologically Relevant				Mutational Signature	COSMIC Signature 11	version 2	0.911																									0				COSMIC Signature (version 2) 11 (91%)		MEL-IPI_Pat151		
